Literature DB >> 8618657

Depression and multiple sclerosis.

A D Sadovnick1, R A Remick, J Allen, E Swartz, I M Yee, K Eisen, R Farquhar, S A Hashimoto, J Hooge, L F Kastrukoff, W Morrison, J Nelson, J Oger, D W Paty.   

Abstract

The objective of the present study were (1) to ascertain the lifetime risk of a depression in a representative group of multiple sclerosis (MS) patients, (2) to assess the morbidity risks for depression among first-degree relatives of these MS patients, and (3) to compare these familial risks for first-degree relatives of MS patients with those for first-degree relatives of a primary depression population, i.e., depression but no MS. We psychiatrically evaluated 221 MS patients (index cases) using a structured clinical interview for the DSM-III-R and calculated the rate and lifetime risk of depression for these index cases using the product limit estimate of survival function. We obtained psychiatric histories for all first-degree relatives of index cases, and we calculated morbidity risks for depression for these relatives using the maximum likelihood approach and compared the risks using the likelihood ratio tests. Index cases had a 50.3% lifetime risk of depression. Morbidity risks for depression among first-degree relatives of index cases were decidedly lower when compared with morbidity risks among first-degree relatives of the reference population. Although there appears to be a very high rate of depression among MS patients, the data for their first-degree relatives do not support a clear genetic basis for this depression, or at least the same genetic basis that probably operates within families when depression occurs in the absence of MS.

Entities:  

Mesh:

Year:  1996        PMID: 8618657     DOI: 10.1212/wnl.46.3.628

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  80 in total

1.  Affective disorders and multiple sclerosis: a controlled study on 65 Italian patients.

Authors:  A Salmaggi; R Palumbo; L Fontanillas; M Eoli; L La Mantia; A Solari; D Pareyson; C Milanese
Journal:  Ital J Neurol Sci       Date:  1998-06

2.  Incidence and predictive factors of depressive symptoms in Alzheimer's disease: the REAL.FR study.

Authors:  C Arbus; V Gardette; C E Cantet; S Andrieu; F Nourhashémi; L Schmitt; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

3.  Depression in multiple sclerosis: a longitudinal analysis.

Authors:  Claudia C Beal; Alexa K Stuifbergen; Adama Brown
Journal:  Arch Psychiatr Nurs       Date:  2007-08       Impact factor: 2.218

4.  Psychometric properties of the Hamilton Depression Rating Scale in multiple sclerosis.

Authors:  Simona Raimo; Luigi Trojano; Daniele Spitaleri; Vittorio Petretta; Dario Grossi; Gabriella Santangelo
Journal:  Qual Life Res       Date:  2015-02-11       Impact factor: 4.147

Review 5.  Complementary and alternative medicine and coping in neuroimmunological diseases.

Authors:  A Apel; B Greim; U K Zettl
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

6.  How Do Pain, Fatigue, Depressive, and Cognitive Symptoms Relate to Well-Being and Social and Physical Functioning in the Daily Lives of Individuals With Multiple Sclerosis?

Authors:  Anna L Kratz; Tiffany J Braley; Emily Foxen-Craft; Eric Scott; John F Murphy; Susan L Murphy
Journal:  Arch Phys Med Rehabil       Date:  2017-07-18       Impact factor: 3.966

7.  Neuropsychological deficits but not coping strategies are related to physical disability in multiple sclerosis.

Authors:  Claus G Haase; Marc Lienemann; Pedro M Faustmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-11-07       Impact factor: 5.270

8.  Self-efficacy as a predictor of self-reported physical, cognitive, and social functioning in multiple sclerosis.

Authors:  Margaret M Schmitt; Yael Goverover; John Deluca; Nancy Chiaravalloti
Journal:  Rehabil Psychol       Date:  2013-12-09

Review 9.  Exercise and multiple sclerosis.

Authors:  Lesley J White; Rudolph H Dressendorfer
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

10.  Factors that influence adherence with disease-modifying therapy in MS.

Authors:  Katherine Treadaway; Gary Cutter; Amber Salter; Sharon Lynch; James Simsarian; John Corboy; Douglas Jeffery; Bruce Cohen; Ken Mankowski; Joseph Guarnaccia; Lawrence Schaeffer; Roy Kanter; David Brandes; Charles Kaufman; David Duncan; Ellen Marder; Arthur Allen; John Harney; Joanna Cooper; Douglas Woo; Olaf Stüve; Michael Racke; Elliot M Frohman
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.